Navigation Links
Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
Date:11/6/2012

ense agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which has completed Phase 1/2 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

CONTACT:  Jennifer Ruddock of Nektar Therapeutics, +1-415-482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
2. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
3. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
4. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
5. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
9. Perrigo Company Announces Appointment Of New Board Of Directors Member
10. Rochester Medical Corporation Announces Decision To Exit The Foley Catheter Business
11. Webcast Alert: Heska Announces Third Quarter 2012 Earnings Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... JUNCTION, N.J. , Nov. 21, 2014 /PRNewswire/ ... company commercializing its European Union approved CytoSorb® cytokine ... worldwide, was awarded the Beacon of Light Award ... Awards Celebration.  Dr. Phillip ... "It is an honor to be recognized by ...
(Date:11/22/2014)... LONG BEACH, Calif. , Nov. 21, 2014   ... implants. Dental implants are often called the gold standard in ... teeth. They are a stable, long-lasting way to restore and ... use dental implants to replace a missing tooth or as ... to completely transform the look and feel of a smile. ...
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired ... nine months and the 3 rd quarter sales ended ... income was $448,000 for the nine months ended September 2014 ... "Even though our 3 rd quarter is usually a ... extends from July into September for many countries worldwide, we ...
Breaking Medicine Technology:CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3
... 2010 The board of directors of Pfizer Inc. (NYSE: ... dividend on the company,s common stock, payable March 1, 2011, ... February 4, 2011.  Pfizer increased the dividend by approximately 11 ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) "This dividend increase is a ...
... Out of hundreds of Medicare Advantage ... SNP) is one of only five plans across the country that ... from the Centers for Medicare and Medicaid Services (CMS). ... and drug plans perform on a scale of one to five, ...
Cached Medicine Technology:Pfizer Declares A 20-Cent First-Quarter 2011 Dividend 2IEHP Earns Highest Rating for Medicare Part D Quality and Performance 2
(Date:11/22/2014)... 2014 (HealthDay News) -- A clinical trial of hydroxyurea ... halted a year early because the results show it ... disease and reduce the risk of stroke. The ... medical centers in the United States and Canada, was ... and Blood Institute (NHLBI). Researchers compared monthly blood ...
(Date:11/22/2014)... FRIDAY, Nov. 21, 2014 (HealthDay News) -- Those air-blown ... germs than conventional paper towels, a new study suggests. ... on the hands of volunteers in order to simulate ... dryers, high-powered "jet-air" dryers or paper towels to dry ... and found higher amounts of germs around both types ...
(Date:11/22/2014)... widely used heart drug digoxin is associated with increased ... the heart rhythm disorder atrial fibrillation but no evidence ... fibrillation is a common form of irregular heartbeat that ... stroke among older Americans. Digoxin has been used for ... the authors of the new study said, and many ...
(Date:11/21/2014)... CRN International, the radio marketing and ... professional to its award-winning team. , Leslie Heinemann, most ... and sales experience to CRN. She will be based ... Director of Strategy and Development, reporting to CRN Managing ... will handle a wide range of territories and market ...
(Date:11/21/2014)... FL (PRWEB) November 21, 2014 Body Well ... announced that it accepts Spafinder massage gift cards ... in room hotel massage in all service areas including throughout ... don't have to go to the spa at all to ... and Founder of Body Well. "We may not be able ...
Breaking Medicine News(10 mins):Health News:Sickle Cell Anemia Treatment So Successful in Kids That Trial Is Halted 2Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 3Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2
... America,s Health (TFAH) released a new report today ... change plan that includes a public health response. This includes ... natural disasters, pollution, and infectious diseases as temperatures and sea ... Climate Change and the Public,s Health report examines U.S. ...
... years of experience in cancer research and patient care, ... released today the most comprehensive, risk-based screening guidelines publicly ... The new recommendations represent the first wave ... the effectiveness of efforts to prevent and detect cancer ...
... MD, a principal investigator at Los Angeles Biomedical Research ... one of India,s highest honors, the "Hind Rattan Award," ... presents annually for "outstanding services, achievements and contributions" by ... Welfare Society will present the honor to Dr. Mehrotra ...
... SCOTTSDALE, Ariz. A new Mayo Clinic study suggests that ... uses wireless technology in diagnosing intestinal disease, is safe ... as cell phones, have been shown to interfere with ... has led medical experts to speculate that capsule endoscopy ...
... world,s fastest supercomputer, Roadrunner, at Los Alamos National ... accelerated petascale computer modeling and simulations of a ... Roadrunner system is now beginning its transition to ... reliability of the U.S. nuclear deterrent. ...
... Park live to be nearly six years old, their ability to ... a study led by Dan MacNulty and recently published online by ... December print issue. The finding challenges a long-held ... It now appears that like human athletes, they are only at ...
Cached Medicine News:Health News:Only Five States Have Plans to Address the Health Impact of Climate Change, New Report Finds 2Health News:Only Five States Have Plans to Address the Health Impact of Climate Change, New Report Finds 3Health News:Only Five States Have Plans to Address the Health Impact of Climate Change, New Report Finds 4Health News:M. D. Anderson redefines screening guidelines for breast, cervical and colorectal cancers 2Health News:M. D. Anderson redefines screening guidelines for breast, cervical and colorectal cancers 3Health News:M. D. Anderson redefines screening guidelines for breast, cervical and colorectal cancers 4Health News:LA BioMed researcher to be honored 2Health News:Mayo Clinic study shows people with heart devices can 'digest' advanced diagnostic technology safely 2Health News:Mayo Clinic study shows people with heart devices can 'digest' advanced diagnostic technology safely 3Health News:Science at the petascale: Roadrunner results unveiled 2Health News:Science at the petascale: Roadrunner results unveiled 3Health News:Wolves lose their predatory edge in mid-life, new U of Minnesota study shows 2
Cholesterol/HDL Standard 50 mg/dl....
For the quantitative determination of High Density Lipoprotein in serum. Available in liquid type. Polyethylene glycol (6000) precipitating reagent. Linearity: 200 mg/dl....
... Intended for the ... in plasma. Two vials, ... Enzymatic, alphaketoglutarate. Uses NADPH ... other plasma compounds. Reaction: ...
... The ProteomeLab XL-A/XL-I functions over a ... strength and pH, delivering more thorough ... operating methodology measures the relative change ... providing an efficient way to measure ...
Medicine Products: